Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
CONCLUSION: Pmab showed more favorable outcomes in patients treated with bevacizumab within the last 6 months. The interval between prior bevacizumab and subsequent anti-EGFR therapy may be useful for determining the optimal anti-EGFR therapy.
PMID: 30359979 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Hayashi K, Mitani S, Taniguchi H, Yasui H, Muro K, Mori K, Gotoda T, Yamazaki K Tags: Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Colorectal Cancer | Epithelial Cancer | Erbitux | Study